Urinary Tract Infection Treatment Market Key Companies and SWOT Analysis by 2031

The urinary tract infection treatment Market size is projected to reach US$ 13.02 billion by 2031 from US$ 10.10 billion in 2023. The market is expected to register a CAGR of 3.2% in 2022–2031. Development of novel alternative treatments such as nutritional supplements for UTI are likely to remain key urinary tract infection treatment market trends.

Urinary Tract Infection Treatment Market Analysis

Urinary Tract Infections (UTIs) occur when bacteria, mostly from the skin or rectum, enter the urethra and infect the urinary tract. Although several parts of the urinary tract can be affected, the most prevalent type of UTI is a bladder infection (cystitis). Kidney infection (pyelonephritis), on the other hand, is less common but more severe than bladder infections. Growing prevalence of UTIs increase the demand for its prevention and treatment therapies such as antibiotics.

Urinary Tract Infection Treatment Market Overview

Advancements in molecular diagnostics technologies such as remote patient monitoring, and artificial intelligence are expected to enhance the efficiency of diagnostic procedures. A majority of the industry players focus on the development and launch of advanced kits and equipment with an aim to improvise the process of home diagnostics. For instance, in February 2024, PathogenDx, launched its D3 Array-UTI test. This test is a multiplexed PCR test that is capable of detecting 26 different pathogens and 12 antibiotic resistance gene markers. The test results can help clinicians deliver rapid treatment for UTI. Additionally, the rising geriatric population is expected to bring an uptake in the demand for UTI treatments in the coming decade.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Urinary Tract Infection Treatment Market: Strategic Insights

Urinary Tract Infection Treatment Market Drivers and Opportunities

Mounting Cases of UTIs to Favor Market

Increasing prevalence of UTI is one of the prominent factors driving the growth of the urinary tract infection treatment market. For instance, according to a study conducted by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020, UTIs accounts for an estimated 6 million physicians visits each year in the US. Propelling incidences of UTIs is a major driver of global urinary tract infection treatment market share.

Increasing R&D Activities– An Opportunity in UTI Treatment

R&D in UTI treatment is expected to offer lucrative growth opportunities for players in the global urinary tract infection treatment market. Further, in February 2020, a new antibiotic treatment for urinary and bacterial infections, developed by Venatorx Pharmaceuticals and Global Antibiotic Research & Development Partnership (GARDP) is under final review by the FDA. The treatment represents a significant advancement in treating complicated urinary tract infections and serious infections caused by highly resistant bacteria.

Urinary Tract Infection Treatment Market Report Segmentation Analysis

Key segments that contributed to the derivation of the urinary tract infection treatment market analysis are drug class, indication, and distribution channel.

• Based on drug class the market is segmented into penicillin and combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, and nutritional supplements. The quinolones segment held the largest market share in 2023.
• By Indication the market is bifurcated into complicated urinary tract infection and uncomplicated urinary tract infection. The complicated urinary tract infection segment held the largest share of the market in 2023.
• In terms of distribution channel, the market is segmented into hospital pharmacies, gynaecology and urology clinics, retail pharmacies and drug stores, online drug stores. The hospital pharmacies segment dominated the market in 2023.

Urinary Tract Infection Treatment Market Share Analysis by Geography

The geographic scope of the urinary tract infection treatment Market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the urinary tract infection treatment Market. The US is estimated to hold the largest share of the North America urinary tract infection treatment market. The growth in the US is estimated due to rising incidence of UTI, the rising development in the field of home diagnostics for UTI, and the presence of the startups offering treatments for UTI. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.  

The regional trends and factors influencing the Urinary Tract Infection Treatment Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Urinary Tract Infection Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Urinary Tract Infection Treatment Market Report Scope

Urinary Tract Infection Treatment Market Players Density: Understanding Its Impact on Business Dynamics

The Urinary Tract Infection Treatment Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Urinary Tract Infection Treatment Market News and Recent Developments

The urinary tract infection treatment Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for urinary tract infection treatment and strategies:

• Allecra Therapeutics announced U.S. FDA approval for EXBLIFEP for the treatment of complicated urinary tract infections, including pyelonephritis, in patients 18 years and older. The company also received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act). The GAIN Act, enacted by the U.S. Congress, incentivizes the creation of new anti-infective therapeutics by providing benefits to manufacturers of Qualified Infectious Disease Products (QIDPs). (Source: Allecra Therapeutics GmbH, Newsletter, 2024).
• NRx Pharmaceuticals announced that FDA accepts Investigational New Drug (IND) application for its NRX-101 for complicated UTIs. The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs. (Source: NRx Pharmaceuticals, Company Website, 2023).

Urinary Tract Infection Treatment Market Report Coverage and Deliverables

The “Urinary Tract Infection Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles